Compare GLDD & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | FLGT |
|---|---|---|
| Founded | 1890 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.6M | 697.3M |
| IPO Year | 2006 | 2016 |
| Metric | GLDD | FLGT |
|---|---|---|
| Price | $12.72 | $28.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | ★ 427.3K | 400.7K |
| Earning Date | 11-04-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.27 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $834,599,000.00 | $315,549,000.00 |
| Revenue This Year | $13.73 | $15.19 |
| Revenue Next Year | $3.56 | $10.58 |
| P/E Ratio | $10.70 | ★ N/A |
| Revenue Growth | 12.53 | ★ 13.61 |
| 52 Week Low | $7.51 | $14.57 |
| 52 Week High | $13.05 | $31.04 |
| Indicator | GLDD | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 62.23 | 57.96 |
| Support Level | $11.47 | $28.65 |
| Resistance Level | $12.29 | $31.04 |
| Average True Range (ATR) | 0.36 | 1.09 |
| MACD | 0.04 | -0.07 |
| Stochastic Oscillator | 80.70 | 34.75 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.